Non-Arteritic Ischemic Optic Neuropathy Treatment Options

No treatment for non-arteritic anterior ischemic optic neuropathy (NAION) has been proven to reliably restore lost vision. Despite decades of research, the condition remains one of the most frustrating in neuro-ophthalmology: a sudden, painless loss of vision in one eye caused by compromised blood flow to the optic nerve head, with no therapy that consistently changes the outcome. What doctors can do is manage the underlying risk factors, protect the other eye, and in some cases offer emerging therapies that show early promise but have not yet cleared the bar of large, controlled trials.

Why the First Hours Matter

Before discussing treatment, the most urgent step when someone develops sudden vision loss with a swollen optic disc is ruling out the arteritic form of ischemic optic neuropathy, which is caused by giant cell arteritis (GCA). GCA requires immediate high-dose steroids to prevent blindness in the other eye, and the two conditions can look similar on exam. A joint position paper from the Spanish Society of Internal Medicine calls this distinction “a diagnostic emergency” because early differentiation between the arteritic and non-arteritic forms determines both treatment and visual prognosis.¹ Blood tests for inflammatory markers (erythrocyte sedimentation rate, C-reactive protein) and sometimes a temporal artery biopsy are used to sort this out quickly. Emerging blood biomarkers like the neutrophil-to-lymphocyte ratio may eventually help clinicians distinguish the two forms more rapidly.²

Once GCA is excluded, the diagnosis of NAION carries a very different prognosis and, unfortunately, a much narrower set of treatment options.

What Happens Without Treatment

NAION does have some capacity for spontaneous improvement, which is part of why proving any treatment works has been so difficult. In a large natural-history study, among patients seen within two weeks of onset who started with poor acuity (worse than about 20/70), roughly 41% showed some improvement by six months.³ That sounds encouraging until you realize that the improvement is often modest, and a sizable minority of patients get worse over time: about 18% of eyes that began with poor acuity deteriorated further within two years. Visual field defects, typically an altitudinal loss where the upper or lower half of vision is cut off, improved in only about a quarter of patients over the same period. The takeaway is that NAION is not universally devastating, but it is unpredictable, and any treatment must outperform this uneven natural recovery.

The Anatomy Behind the Problem

Understanding who gets NAION helps explain why treatment is so challenging. The optic nerve head receives blood from tiny branches of the posterior ciliary arteries, and in people whose optic disc is structurally crowded, with a small or absent central cup, the nerve fibers are packed tightly into a confined space. When swelling starts, it compresses neighboring nerve fibers and their blood supply in a vicious cycle. Multiple studies have confirmed that a small cup-to-disc ratio is a strong predisposing factor. One study found that eyes with the smallest cups had more than 46 times the odds of developing NAION compared to eyes with normal-sized cups.⁴ A separate study confirmed that smaller disc area and smaller cupping were independent risk factors.⁵

This structural vulnerability is why surgical decompression was once considered a logical solution, and why its failure was so instructive.

Optic Nerve Decompression Surgery

In the 1990s, the Ischemic Optic Neuropathy Decompression Trial (IONDT) tested whether cutting slits in the sheath surrounding the optic nerve could relieve the compartment-like pressure thought to be worsening the damage. The trial enrolled 258 patients and was stopped early because surgery was not helping. At six months, about 43% of patients assigned to careful follow-up alone had gained three or more lines of visual acuity, compared to only 32% in the surgery group.⁶ Surgery patients also experienced serious complications, including central retinal artery occlusion during the procedure and, in two cases, immediate and lasting loss of all light perception. Pain occurred in 17% of surgical patients at one week versus 3% of those receiving no surgery. A Cochrane review concluded there is no evidence of benefit, and optic nerve decompression for NAION is now effectively abandoned.

Corticosteroids

Steroids remain the most debated treatment for NAION. The reasoning is intuitive: disc swelling compresses neighboring nerve fibers, so reducing inflammation and edema should limit the damage. Some observational reports have suggested that oral or intravitreal steroids accelerate the resolution of disc edema.⁷ But when the data were pooled in a meta-analysis, steroids did not significantly improve visual acuity.⁸

That does not necessarily mean steroids are useless in every patient. Some neuro-ophthalmologists still prescribe a short oral steroid course for patients seen very early after onset, on the theory that any disc-edema relief during the critical swelling window could prevent secondary damage. Others point to the meta-analysis results and the real side effects of systemic steroids, especially in a population already prone to diabetes and hypertension, and prefer to watch and wait. This is one of those areas where two experienced specialists may give opposite advice, and both can cite evidence for their position.

Aspirin and Second-Eye Protection

Perhaps the most actionable finding in NAION management involves the other eye. The fellow eye is at meaningful risk: it almost always has the same crowded disc anatomy, and the same systemic risk factors are still present. One study found that among patients not taking aspirin, 50% experienced NAION in the second eye, compared to 18% of those taking 325 mg aspirin daily. The average time to second-eye involvement was also much longer with aspirin, about 156 months versus 63 months without it.⁹

This was not a randomized controlled trial, so the evidence is not as strong as it might sound. Still, given the low risk profile of daily aspirin for most people and the devastating consequences of bilateral NAION, many clinicians prescribe it. Patients with contraindications to aspirin (bleeding disorders, active ulcers) need individual risk-benefit discussions.

Anti-VEGF Injections

Injections of anti-vascular endothelial growth factor (anti-VEGF) drugs into the eye are a mainstay for conditions like wet macular degeneration, and researchers have explored them in acute NAION as well. The rationale is that VEGF levels rise in the swollen disc, and blocking them might reduce edema and improve blood flow. A retrospective study using intravitreal aflibercept found that treated patients had significantly better visual acuity outcomes and faster resolution of disc swelling compared to untreated patients, though visual field improvements were not statistically different between groups.¹⁰ A smaller study using a single injection of ranibizumab reported visual gain in 14 of 17 eyes over a year of follow-up, with dramatic thinning of the swollen nerve fiber layer.¹¹

These results are intriguing, but they come from small, uncontrolled or retrospective studies. Without a proper randomized trial, it is hard to know how much of the improvement reflects treatment versus the natural recovery described earlier. Anti-VEGF injections for NAION remain off-label and experimental.

Neuroprotective Drug Trials

The idea behind neuroprotection is straightforward: even if the initial ischemic event kills some nerve fibers immediately, many others are damaged but still alive. A drug that shields those fragile cells from delayed death could preserve vision that would otherwise be lost in the days and weeks following onset.

Brimonidine, a glaucoma eye drop with known neuroprotective properties in animal models, was tested in a three-month randomized trial. Visual acuity showed no significant difference between the brimonidine and placebo groups, though there were non-significant trends toward better visual fields in the treatment arm.¹²

A more ambitious effort involved QPI-1007, an intravitreal injection designed to silence a gene involved in programmed cell death of retinal ganglion cells. A phase 2/3 randomized, sham-controlled trial found no overall difference in the proportion of participants losing significant vision at six months. However, a pre-planned subgroup analysis of patients who started with worse vision showed significantly less visual loss in the treated groups compared to sham, along with better preservation of visual fields.¹³ This is the kind of result that keeps a drug program alive: it failed the primary endpoint but showed enough signal in a subset of patients that further development remains plausible. Whether it leads anywhere remains to be seen.

Managing the Risk Factors You Can Control

Given the lack of a proven acute treatment, risk factor modification is arguably the most impactful thing a patient and their doctor can do after a first episode of NAION. The goal is twofold: reduce the chance of worsening in the affected eye and protect the fellow eye.

Blood Pressure Timing

NAION is famously a “wake-up stroke of the eye.” A large proportion of patients discover their vision loss upon opening their eyes in the morning. This observation led researchers to investigate nocturnal blood pressure dips. The finding: in people who already have vascular risk factors, a pronounced drop in blood pressure during sleep may reduce blood flow to the optic nerve head below a critical threshold.¹⁴ This has led to the practical recommendation that patients who have had NAION avoid taking blood pressure medications at bedtime, shifting them to morning dosing instead.¹⁵ This is one of those recommendations that is widely practiced but based more on pathophysiological reasoning than on randomized trial data. It is simple enough that most clinicians adopt it.

Sleep Apnea

Obstructive sleep apnea (OSA) is one of the strongest independent risk factors for NAION. A meta-analysis found that people with OSA had more than six times the odds of developing NAION compared to those without it.¹⁶ An earlier prospective study found sleep apnea in 71% of NAION patients, compared to 18% of matched controls.¹⁷ The link makes physiological sense: repeated episodes of oxygen deprivation overnight, combined with swings in blood pressure and intracranial pressure, could push a vulnerable optic nerve over the edge. One cohort study found that OSA patients not treated with CPAP had a 16% increased hazard of developing NAION compared to those without OSA.¹⁸

Getting tested for sleep apnea after a NAION diagnosis is now considered standard practice. If OSA is found, treating it with CPAP or other therapies addresses a modifiable risk factor that benefits the eye, the heart, and general health simultaneously.

Semaglutide and GLP-1 Drugs

A newer and more controversial concern is the possible association between semaglutide (sold as Ozempic and Wegovy) and NAION. A study from Mass Eye and Ear found that patients prescribed semaglutide had a substantially higher risk of developing NAION. Among overweight or obese patients specifically, those on semaglutide had a cumulative incidence of about 6.7% over three years compared to 0.8% in a matched group not taking GLP-1 drugs.¹⁹ A study examining disc anatomy in GLP-1-associated NAION cases found the same small-cup anatomy seen in other NAION patients, suggesting the drug may act as a trigger in anatomically predisposed individuals rather than causing a fundamentally different disease.⁴

This finding is still being debated. The original study was retrospective and drawn from a single institution, and the absolute numbers of NAION cases were small. Millions of people take semaglutide, and NAION remains rare. But for someone who has already had NAION in one eye and has a crowded disc in the other, this is the kind of risk worth discussing with their prescriber.

Emerging and Experimental Approaches

Stem Cell Therapy

Several early-phase studies have explored whether stem cells, particularly bone marrow-derived mesenchymal stem cells, can rescue or regenerate damaged optic nerve tissue. In one open-label study (the SCOTS trial), 80% of patients with NAION who received bone marrow-derived stem cells reported improvement in binocular vision, with an average gain of about 3.5 lines on the eye chart.²⁰ A separate phase II trial using intravitreal allogeneic mesenchymal stem cells noted visual improvement in four patients, with increases in electrical signals from the optic nerve in three.²¹

These numbers sound exciting, but context matters enormously. Neither study had a control group receiving sham treatment, so the results cannot be separated from the natural improvement that happens in a significant fraction of NAION patients regardless of intervention. Stem cell therapy for optic neuropathies remains at a proof-of-concept stage.²² Patients should be wary of clinics marketing unproven stem cell treatments at high out-of-pocket cost.

Electrical Stimulation

Transcorneal and transpalpebral electrical stimulation, delivering low-level electrical currents through or near the eye, has been explored for various optic nerve diseases. Animal research suggests it can promote survival of retinal ganglion cells and boost blood flow.²³ An early clinical study found that visual acuity improved in some NAION patients after transcorneal stimulation without major complications.²⁴ A recent case report using transpalpebral stimulation (through the eyelid) showed progressive improvement in visual field sensitivity over 60 days of treatment.²⁵ This is tantalizing but extremely preliminary, a single case report does not establish efficacy. Larger controlled studies are needed before electrical stimulation becomes a standard recommendation.

What Advanced Imaging Can and Cannot Do

Optical coherence tomography angiography (OCT-A) has become an important tool for understanding what happens to the blood vessels around the optic disc in NAION. It can map the tiny capillaries of the optic nerve head without injecting dye. In acute NAION, OCT-A reveals dilated superficial capillaries and obscured deeper layers due to swelling. In the later stages, those capillaries thin out, and the areas of reduced blood flow correlate with the location of visual field defects in about 80% of cases.²⁶ Other studies have confirmed that the peripapillary vessel density drops significantly in NAION eyes compared to healthy controls and the unaffected fellow eye, with temporal sectors often hit hardest.²⁷

OCT-A does not change the acute treatment, but it is increasingly useful for tracking disease progression, confirming the diagnosis, and identifying subtle changes in the fellow eye that might predict future risk. Researchers are also studying whether OCT-A patterns can help distinguish NAION from demyelinating optic neuritis, which has a different treatment and prognosis.²⁸

Low Vision Rehabilitation

Given the current state of treatment, practical support for living with reduced vision deserves more attention than it typically receives. Many patients with NAION lose a significant portion of the visual field in one eye, and some face bilateral involvement over time. Early referral to low vision services can help improve functional outcomes, including reading, driving safety assessments, workplace accommodations, and use of magnifying or adaptive devices.²⁹ These services are underutilized partly because the medical conversation tends to focus on whether vision can be recovered rather than how to optimize the vision that remains. For many NAION patients, especially those whose affected eye stabilizes with a persistent field defect, rehabilitation makes a greater practical difference than any pharmacologic intervention currently available.

PDE5 Inhibitors and Vision Loss Fears

Drugs like sildenafil (Viagra), tadalafil, and vardenafil have long carried warnings about NAION after case reports of vision loss following use. However, a pooled analysis drawing on safety data from more than 13,000 men in clinical trials and over 35,000 patient-years of observation in epidemiological studies estimated the incidence of NAION among sildenafil users at about 2.8 cases per 100,000 patient-years, a figure similar to the background rate in the general population of men over 50.³⁰ The data do not support an increased incidence of NAION in men who took sildenafil for erectile dysfunction. That said, most clinicians still advise caution in someone who has already had NAION in one eye and has a small cup-to-disc ratio in the other, on the principle that even a theoretical vasodilatory trigger is best avoided when the stakes are that high. For people without a history of NAION, the population-level data are reassuring.